Guggenheim upgraded Neumora Therapeutics (NMRA) to Buy from Neutral with a $14 price target following the “compelling” preclinical obesity data reported by the company. The firm views the company’s NLRP3i program in obesity and related disorders as “a clear driver to value creation,” the analyst tells investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NMRA:
- Promising Preclinical Data and Strategic Focus Support Buy Rating for Neumora Therapeutics
- Neumora Therapeutics Begins Phase 1 Study for NMRA-898
- Neumora Therapeutics initiates Phase 1 clinical study of NMRA-988
- Neumora Reports Positive Preclinical Results for NMRA-215
- Neumora Therapeutics’ NMRA-215 shows weight loss efficacy